Paolo Tarantino: Interesting Phase 2 Trial of 1L Treatment for PDL1- mTNBC Out in Nature Medicine
Paolo Tarantino, 2025 Yvonne ‘Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Interesting phase 2 trial of 1L taxol/atezo/beva for (mostly) PDL1- mTNBC (n=100) out in Nature Medicine.
ORR 63%, mPFS 11 months, mOS 27 months. VEGF inhibition is SO back in breast oncology.
Glad to have had the chance to review this paper.”
Title: Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
Authors: María Gion, Isabel Blancas, Patricia Cortez-Castedo, Alfonso Cortés-Salgado, Frederik Marmé, Salvador Blanch, Serafín Morales, Nieves Díaz, Isabel Calvo-Plaza, Sabela Recalde, Alejandro Martínez-Bueno, Manuel Ruiz-Borrego, Elisenda Llabrés, María Teresa Taberner, Michelino de Laurentiis, Silvia García-Vicente, José Antonio Guerrero, Olga Boix, Jose Rodríguez-Morató, Miguel Sampayo-Cordero, Gabriele Antonarelli, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
You can read the Full Article on Nature Medicine
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023